Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 7:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stroke Prevention Clear all
Recruiting Phase 3 Interventional

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

NCT07626411
View directory record Official record
Conditions
Atrial Fibrillation (AF)
Interventions
REGN7508, Apixaban, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
15,364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
32
States / cities
Alexander City, Alabama • Dothan, Alabama • Glendale, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 25, 2026, 7:17 PM EDT
Completed Phase 2 Interventional Results available

Poststroke Depression in Hemorrhagic Stroke

NCT03826875
View directory record Official record
Conditions
Stroke Hemorrhagic, Depression
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 25, 2026, 7:17 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

NCT00403767
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Embolism
Interventions
Rivaroxaban, Warfarin, Matching placebo for Rivaroxaban arm (Warfarin placebo), Matching placebo for Warfarin arm (Rivaroxaban placebo)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
14,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
295
States / cities
Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 292 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Sep 25, 2026, 7:17 PM EDT
Completed Phase 3 Interventional

Vitamin Therapy for Prevention of Stroke

NCT00004734
View directory record Official record
Conditions
Stroke, Cerebral Infarction, Myocardial Infarction
Interventions
pyridoxine, cyanocobalamin, folic acid multivitamin
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
35 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 25, 2026, 7:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dissemination and Implementation of Stroke Prevention Looking at the Care Environment

NCT04173026
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Provider-level intervention, Patient-level intervention
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
2 Years to 7 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
15
States / cities
Little Rock, Arkansas • Oakland, California • Wilmington, Delaware + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 25, 2026, 7:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Prevention and Treatment of Patient Before, During, and After Covid-19 Infection

NCT05043324
View directory record Official record
Conditions
Covid19
Interventions
AntiCov-220, AntiCov-220 (placebo)
Drug
Lead sponsor
Nguyen Thi Trieu, MD
Individual
Eligibility
16 Years to 82 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 25, 2026, 7:17 PM EDT
Completed Phase 3 Interventional Results available

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

NCT01776424
View directory record Official record
Conditions
Prevention & Control
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Aspirin placebo, Rivaroxaban placebo, Pantoprazole, Pantoprazole placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
27,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
53
States / cities
Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2022 · Synced Sep 25, 2026, 7:17 PM EDT
Completed No phase listed Observational

Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist

NCT02687854
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Apixaban, Vitamin K antagonist
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
18,591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Sep 25, 2026, 7:17 PM EDT
Completed Phase 3 Interventional

Carotid Artery Revascularization Using the Boston Scientific EPI Filter Wire EZ™ and the EndoTex™ NexStent™

NCT00600327
View directory record Official record
Conditions
Transient Ischemic Attack, Thromboembolic Stroke, Stroke Prevention
Interventions
EndoTex™ NexStent™, Filter Wire EZ™
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
15
States / cities
Phoenix, Arizona • Mountain View, California • Newport Beach, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2008 · Synced Sep 25, 2026, 7:17 PM EDT
Completed No phase listed Observational

Global Anticoagulant Registry in the Field

NCT01090362
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Thrombosis Research Institute
Other
Eligibility
18 Years and older
Enrollment
57,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 25, 2026, 7:17 PM EDT
Terminated Phase 3 Interventional Results available

AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke

NCT03192215
View directory record Official record
Conditions
Stroke
Interventions
Apixaban, Aspirin
Drug
Lead sponsor
Columbia University
Other
Eligibility
45 Years and older
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
165
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Sep 25, 2026, 7:17 PM EDT
Completed Phase 3 Interventional Results available

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

NCT01674647
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
66
States / cities
Mobile, Alabama • Scottsdale, Arizona • East Palo Alto, California + 58 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Sep 25, 2026, 7:17 PM EDT
Completed Not applicable Interventional

Preventing Post-Stroke Depression

NCT00071643
View directory record Official record
Conditions
Depression, Cerebrovascular Accident
Interventions
Problem Solving Therapy, Escitalopram, Placebo
Behavioral · Drug · Other
Lead sponsor
Robert G. Robinson
Other
Eligibility
31 Years to 89 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
3
States / cities
Chicago, Illinois • Iowa City, Iowa • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Sep 25, 2026, 7:17 PM EDT
Completed No phase listed Observational

Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients

NCT03374540
View directory record Official record
Conditions
Nonvalvular Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
78,517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Multiple Locations, Washington
Source: ClinicalTrials.gov public record
Updated Aug 16, 2020 · Synced Sep 25, 2026, 7:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Home Monitoring for Atrial Fibrillation Using a Microlife Blood Pressure Monitor

NCT00861354
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Microlife blood pressure monitor with AF detection (Microlife AFIB MLU3MQ1)
Device
Lead sponsor
Microlife
Industry
Eligibility
21 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Flushing, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2010 · Synced Sep 25, 2026, 7:17 PM EDT
Withdrawn Phase 2 Interventional

Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli

NCT02378623
View directory record Official record
Conditions
Patent Foramen Ovale, Cardiac Implantable Electronic Device
Interventions
Apixaban, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 25, 2026, 7:17 PM EDT
Completed Phase 2 Interventional

Hydroxyurea to Prevent Stroke in Children With Sickle Cell Anemia and Elevated TCD Flow Velocity

NCT00402480
View directory record Official record
Conditions
Stroke
Interventions
Hydroxyurea
Drug
Lead sponsor
Duke University
Other
Eligibility
3 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 25, 2026, 7:17 PM EDT
Completed Not applicable Interventional

Telestroke at Comprehensive Stroke Center During the COVID-19 Pandemic

NCT04761874
View directory record Official record
Conditions
Stroke, Acute
Interventions
Telestroke
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Edina, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Sep 25, 2026, 7:17 PM EDT
Terminated Not applicable Interventional Results available

Impact of Fever Prevention in Brain Injured Patients

NCT02996266
View directory record Official record
Conditions
Fever, Ischemic Stroke, Intracerebral Hemorrhage, Subarachnoid Hemorrhage
Interventions
Targeted Temperature Management, Standard Care
Device · Other
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years to 85 Years
Enrollment
686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
28
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 25, 2026, 7:17 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"

NCT02671461
View directory record Official record
Conditions
Thrombosis
Interventions
BMS-986141, Aspirin, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
27
States / cities
Phoenix, Arizona • Newport Beach, California • Newark, Delaware + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Sep 25, 2026, 7:17 PM EDT
Enrolling by invitation No phase listed Observational

Cardiac Abnormalities in Stroke Prevention and Risk of Recurrence

NCT06398366
View directory record Official record
Conditions
Cryptogenic Stroke
Interventions
Not listed
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Sep 25, 2026, 7:17 PM EDT
Recruiting Not applicable Interventional

Effect of NMES on Balance and Fall Risk in Chronic Stroke

NCT04957355
View directory record Official record
Conditions
Chronic Stroke
Interventions
Neuromuscular electrical stimulation (NMES) or Functional electrical stimulation (FES)
Device
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 25, 2026, 7:17 PM EDT
Completed No phase listed Observational

Real-world Comparative Effectiveness of Rivaroxaban Versus VKA

NCT02690155
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Rivaroxaban (Xarelto, BAY59-7939), VKA (Vitamin K antagonist)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
38,831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Sep 25, 2026, 7:17 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Aspirin in Reducing Events in the Elderly-Extension (ASPREE-XT)

NCT07224347
View directory record Official record
Conditions
Functional Disability, Dementia, Heart Disease, Stroke, Cancer, Bleeding, Depression, Frailty
Interventions
Not listed
Lead sponsor
Anne Murray
Other
Eligibility
65 Years and older
Enrollment
19,114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
22
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 25, 2026, 7:17 PM EDT